Plain-English translation of NCT07369011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help people with moderate to severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) who also struggle with excess weight. The medication is given as a weekly injection under the skin. Researchers want to learn whether this treatment can improve sleep apnea and help with weight management in people who cannot or do not want to use a breathing machine, as well as in those already using one.
Many people with sleep apnea also carry excess weight, and the two conditions can make each other worse. While breathing machines help some people, others cannot or will not use them. This trial aims to see if the new treatment offers another option for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo (inactive injection) once per week for about 76 weeks. Depending on whether you use a breathing machine or not, you would be in one of two study groups. You will have regular visits to receive your injection and have your sleep apnea and weight monitored throughout the study.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States